Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Non-Current Debt: 2020-2021

  • Mereo BioPharma Group's Non-Current Debt fell 9.03% to $19.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $19.4 million, marking a year-over-year decrease of 9.03%. This contributed to the annual value of $19.4 million for FY2021, which is 6.46% down from last year.
  • Latest data reveals that Mereo BioPharma Group reported Non-Current Debt of $19.4 million as of Q4 2021, which was down 22.64% from $25.1 million recorded in Q2 2021.
  • In the past 5 years, Mereo BioPharma Group's Non-Current Debt ranged from a high of $25.1 million in Q2 2021 and a low of $18.0 million during Q2 2020.
  • Over the past 2 years, Mereo BioPharma Group's median Non-Current Debt value was $20.4 million (recorded in 2020), while the average stood at $20.9 million.
  • Over the last 5 years, Mereo BioPharma Group's Non-Current Debt had its largest YoY gain of 39.16% in 2021, and its largest YoY loss of 9.03% in 2021.
  • Quarterly analysis of 2 years shows Mereo BioPharma Group's Non-Current Debt stood at $21.3 million in 2020, then dropped by 9.03% to $19.4 million in 2021.
  • Its last three reported values are $19.4 million in Q4 2021, $25.1 million for Q2 2021, and $21.3 million during Q4 2020.